Get started
Author

Soren Can Tamer

Observed names: S. C. Tamer, SC Tamer, Søren C Tamer, Søren C. Tamer, Søren Can Tamer, Søren Tamer, Tamer, S.C.
OpenAlex ID: A5113920839
Efficacy and Safety of Insulin Degludec in a Flexible Dosing Regimen vs Insulin Glargine in Patients With Type 1 Diabetes (BEGIN: Flex T1): A 26-Week Randomized, Treat-to-Target Trial With a 26-Week Extension
2013 · Chantal Mathieu, Priscilla Hollander, et al. · The Journal of Clinical Endocrinology & Metabolism · 218
PDF
Ofatumumab, a human anti‐CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease‐modifying antirheumatic drugs: Results of a randomized, double‐blind, placebo‐controlled, phase I/II study
2010 · Mikkel Østergaard, Bo Baslund, et al. · Arthritis & Rheumatism · 109
Insulin degludec compared with insulin glargine in insulin‐naïve patients with type 2 diabetes: A 26‐week, randomized, controlled, P an‐ A sian, treat‐to‐target trial
2013 · Yukiko Onishi, Yasuhiko Iwamoto, et al. · Journal of Diabetes Investigation · 100
PDF
Improved Postprandial Glycemic Control with Faster-Acting Insulin Aspart in Patients with Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion
2017 · Bruce W. Bode, Joseph A. Johnson, et al. · Diabetes Technology & Therapeutics · 72
PDF
Insulin Detemir Results in Less Weight Gain than NPH Insulin When??Used in Basal-Bolus Therapy for??Type??2 Diabetes??Mellitus, and this??Advantage Increases with Baseline??Body??Mass Index
2007 · Katarina Ra??lov??, Soren Can Tamer, et al. · Clinical Drug Investigation · 66
Adding fast‐acting insulin aspart to basal insulin significantly improved glycaemic control in patients with type 2 diabetes: A randomized, 18‐week, open‐label, phase 3 trial (onset 3)
2017 · Helena W. Rodbard, Devjit Tripathy, et al. · Diabetes Obesity and Metabolism · 45
PDF
Risk Mitigation Strategy for Concizumab Clinical Trials after Pause Due to Non-Fatal Thrombotic Events
2020 · Stephanie Valer Seremetis, Katarina Cepo, et al. · Blood · 24
Die Hinzunahme von schnell wirksamem Insulin aspart (Faster aspart) zu Basalinsulin bewirkte eine signifikant verbesserte Blutzuckereinstellung bei Erwachsenen mit Typ 2 Diabetes: die onset® 3-Studie
2017 · E Wizemann, H Rodbard, et al. · Diabetologie und Stoffwechsel
L’ajout d’insuline Faster Aspart améliore significativement le contrôle glycémique chez des patients diabétiques de type 2 insuffisamment contrôlés sous insuline basale : Onset (R) 3
2017 · Lucy Chaillous, Helena Rodbard, et al. · Diabetes & Metabolism
Verbesserte postprandiale Blutzuckereinstellung mit schneller wirksamem Insulin aspart vs. Insulin aspart bei Menschen mit Typ 1 Diabetes und kontinuierlicher subkutaner Insulininfusion (CSII)
2016 · T Danne, B Bode, et al. · Diabetologie und Stoffwechsel
Reply
2010 · M. Østergaard, B. Baslund, et al. · Arthritis & Rheumatism
Reduced frequency and severity of infusion-related adverse events after change in ofatumumab infusion regimen - Reply to comment by Abeles (letter)
2010 · Østergaard, Mikkel, Baslund, Bo, et al. · Research at the University of Copenhagen (University of Copenhagen)
Bei Typ 2 Diabetes führt Insulindetemir in einer Basis-Bolus-Therapie insbesondere bei sehr adipösen Patienten zu einer geringeren Gewichtszunahme als NPH-Insulin
2006 · SC Tamer, D Karl, et al. · Diabetologie und Stoffwechsel
Works count: 14
Citation count: 634
H-index: 7
I10-index: 7
Year
Topic
Type